Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Doxorubicin Clear all
Completed Phase 1 Interventional

SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer

NCT00005822
View directory record Official record
Conditions
Breast Cancer
Interventions
doxorubicin hydrochloride, semaxanib, conventional surgery, radiation therapy, tamoxifen
Drug · Procedure · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Jul 23, 2026, 5:19 PM EDT
Active, not recruiting Not applicable Interventional

Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer

NCT01928589
View directory record Official record
Conditions
Breast Cancer, Adenocarcinoma of the Breast
Interventions
PBI with sequential chemotherapy, PBI with concurrent chemotherapy
Other
Lead sponsor
Richard Zellars
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Fort Wayne, Indiana • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 23, 2026, 5:19 PM EDT
Active, not recruiting Phase 1 Interventional

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

NCT02203526
View directory record Official record
Conditions
Primary Central Nervous System Lymphoma
Interventions
Isavuconazole, TEDDI, Rituximab, Cytarabine, TEDD, Ibrutinib (Arms 2, 3 and 4), Methotrexate, Ibrutinib (Arm 1 - Closed with Amendment G), Ibrutinib (Arm 4)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 5:19 PM EDT
Completed Phase 1 Interventional

MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme

NCT01851733
View directory record Official record
Conditions
Glioblastoma
Interventions
MRI-guided Laser Heat Ablation (MLA), Doxorubicin, Blood draw - dendritic cells, Dynamic Susceptibility Contrast Magnetic Resonance Imaging
Device · Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Jul 23, 2026, 5:19 PM EDT
Completed Phase 2 Interventional

Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer

NCT00049114
View directory record Official record
Conditions
Inflammatory Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
doxorubicin hydrochloride, cyclophosphamide, tipifarnib, filgrastim, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Jul 23, 2026, 5:19 PM EDT
Completed Phase 3 Interventional Results available

Docetaxel in Breast Cancer

NCT00312208
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel,doxorubicin, cyclophosphamide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
3,299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 29, 2013 · Synced Jul 23, 2026, 5:19 PM EDT
Withdrawn Phase 1 Interventional

Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer

NCT00074139
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, docetaxel, doxorubicin hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 69 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Jul 23, 2026, 5:19 PM EDT
Completed Phase 2 Interventional Results available

Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease

NCT01404936
View directory record Official record
Conditions
Lymphoma
Interventions
Interferon-2A, Adriamycin, Bleomycin, Velban, Dacarbazine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Jul 23, 2026, 5:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

NCT00182767
View directory record Official record
Conditions
Fallopian Tube Cancer, Female Reproductive Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
ixabepilone, pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
5
States / cities
Farmington, Connecticut • Albany, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Jul 23, 2026, 5:19 PM EDT
Completed Phase 2 Interventional

Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer

NCT00286247
View directory record Official record
Conditions
Locally Advanced Breast Cancer (LABC)
Interventions
INGN 201
Genetic
Lead sponsor
Introgen Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2008 · Synced Jul 23, 2026, 5:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Olaratumab in Soft Tissue Sarcoma

NCT01185964
View directory record Official record
Conditions
Sarcoma, Soft Tissue
Interventions
Olaratumab, doxorubicin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Jul 23, 2026, 5:19 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

NCT04594798
View directory record Official record
Conditions
DLBCL, Lymphoma, B-Cell
Interventions
Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
Drug
Lead sponsor
University of Rochester
Other
Eligibility
75 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 23, 2026, 5:19 PM EDT
Not listed Phase 2 Interventional

A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

NCT00333008
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin
Interventions
Doxil, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Pegfilgrastim
Drug
Lead sponsor
The Alvin and Lois Lapidus Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Randallstown, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2006 · Synced Jul 23, 2026, 5:19 PM EDT
Completed Phase 1 Interventional

Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer

NCT00976131
View directory record Official record
Conditions
Breast Cancer
Interventions
CoQ10, CoQ10 Placebo, Doxorubicin, Cyclophosphamide
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Jul 23, 2026, 5:19 PM EDT
Completed Phase 2 Interventional

Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma

NCT00051571
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
SGN-15, Docetaxel
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
9
States / cities
Los Angeles, California • Greenwich, Connecticut • Fort Myers, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2011 · Synced Jul 23, 2026, 5:19 PM EDT
Completed Phase 1Phase 2 Interventional

VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin

NCT00004030
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
VX-853, pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Jul 23, 2026, 5:19 PM EDT
Completed Phase 2 Interventional

Osteosarcoma1999-A Study Of Intensive Chemotherapy for Osteosarcoma

NCT00145639
View directory record Official record
Conditions
Osteosarcoma
Interventions
Ifosfamide, Carboplatin, Doxorubicin, Limb Sparing
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 25 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
3
States / cities
Little Rock, Arkansas • St Louis, Missouri • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Jul 23, 2026, 5:19 PM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

NCT00628251
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
AZD2281, Liposomal Doxorubicin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Boca Raton, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Jul 23, 2026, 5:19 PM EDT
Completed No phase listed Observational

Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor Burden

NCT01136824
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Questionnaires
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Jul 23, 2026, 5:19 PM EDT
Completed Phase 2 Interventional Results available

Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma

NCT00267046
View directory record Official record
Conditions
Sarcoma, Oral Mucositis
Interventions
Palifermin, Placebo, Adriamycin (Doxorubicin), Ifosfamide, Vincristine, Cisplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Jul 23, 2026, 5:19 PM EDT
Completed Phase 1 Interventional

Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)

NCT01324180
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Metformin, Vincristine, Dexamethasone, PEG-asparaginase, Doxorubicin, Intrathecal chemotherapy
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
1 Year to 30 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • St. Petersburg, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2017 · Synced Jul 23, 2026, 5:19 PM EDT
Terminated Phase 2 Interventional Results available

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

NCT01925612
View directory record Official record
Conditions
Lymphoma, B-cell, Lymphoma, Large B-cell, Diffuse
Interventions
brentuximab vedotin, rituximab, vincristine, cyclophosphamide, prednisone, doxorubicin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
36
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Jul 23, 2026, 5:19 PM EDT
Completed Phase 1 Interventional

A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

NCT01815294
View directory record Official record
Conditions
Neoplasms, Neoplasms, Ovarian, Neoplasms, Breast, Advanced or Refractory Solid Malignancies
Interventions
DOXIL/CAELYX (doxorubicin) Treatment Sequence AB, DOXIL/CAELYX (doxorubicin) Treatment Sequence BA
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Jul 23, 2026, 5:19 PM EDT
Completed Phase 3 Interventional

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

NCT00005970
View directory record Official record
Conditions
Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
Interventions
Aromatase Inhibition Therapy, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Tamoxifen Citrate, Trastuzumab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
3,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
154
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Jul 23, 2026, 5:19 PM EDT